Original Research| Volume 36, ISSUE 1, P103-108, January 2022

Propofol Versus Remifentanil Sedation for Transcatheter Aortic Valve Replacement: A Single Academic Center Experience


      Comparison of remifentanil versus propofol for sedation during transcatheter aortic valve replacement (TAVR) procedures to analyze the risk of sedation-related hypoxemia and hypotension. Secondary outcomes included the rate of conversion to general anesthesia, procedure length, rate of intensive care unit (ICU) admission, ICU and hospital lengths of stay, and 30-day mortality.


      Retrospective cohort study.


      A single tertiary teaching hospital.


      Two hundred fifty-nine patients who had propofol or remifentanil sedation for TAVR between March 2017 and March 2020.



      Measurements and Main Results

      There were 130 patients (50.2%) in the propofol cohort and 129 patients (49.8%) in the remifentanil cohort. The primary outcomes were oxygen saturation nadir values and vasopressor infusion use. Remifentanil was associated with a lower oxygen saturation nadir, as compared to propofol (91.3% v . 95.4%, p < 0.001). Risk factors associated with hypoxemia (defined as <92%) were body mass index (p = 0.0004), obstructive sleep apnea (p = 0.004), and remifentanil maintenance (p < 0.001). Vasopressor infusion use was significantly higher with propofol (64.9% v . 8.5%, p < 0.001). Propofol maintenance and angiotensin-converting enzyme inhibitor/angiotensin II receptor-blocker use were the only variables identified as risk factors for vasopressor use (p < 0.001 and p = 0.009).


      For patients undergoing TAVR with conscious sedation, remifentanil was associated with more hypoxemia while propofol was associated with a higher rate of vasopressor use.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Cardiothoracic and Vascular Anesthesia
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Mayr NP
        • Michel J
        • Bleiziffer S
        • et al.
        Sedation or general anesthesia for transcatheter aortic valve implantation (TAVI).
        J Thorac Dis. 2015; 7: 1518-1526
        • Miles LF
        • Joshi KR
        • Ogilvie EH
        • et al.
        General anaesthesia vs. conscious sedation for transfemoral aortic valve implantation: A single UK centre before-and-after study.
        Anaesthesia. 2016; 71: 892-900
        • D'Errigo P
        • Ranucci M
        • Covello RD
        • et al.
        Outcome after general anesthesia versus monitored anesthesia care in transfemoral transcatheter aortic valve replacement.
        J. Cardiothorac Vasc Anesth. 2016; 30: 1238-1243
        • Butala NM
        • Chung M
        • Secemsky EA
        • et al.
        Conscious sedation versus general anesthesia for transcatheter aortic valve replacement: Variation in practice and outcomes.
        JACC Cardiovasc Interv. 2020; 13: 1277-1287
        • Hyman MC
        • Vemulapalli S
        • Szeto WY
        • et al.
        Conscious sedation versus general anesthesia for transcatheter aortic valve replacement: Insights from the National Cardiovascular Data Registry Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry.
        Circulation. 2017; 136: 2132-2140
        • Bhananker SM
        • Posner KL
        • Cheney FW
        • et al.
        Injury and liability associated with monitored anesthesia care: A closed claims analysis.
        Anesthesiology. 2006; 104: 228-234
        • Beasley R
        • Chien J
        • Douglas J
        • et al.
        Thoracic Society of Australia and New Zealand oxygen guidelines for acute oxygen use in adults: “Swimming between the flags.
        Respirology. 2015; 20: 1182-1191
        • Smith I
        • Avramov MN
        • White PF.
        A comparison of propofol and remifentanil during monitored anesthesia care.
        J Clin Anesth. 1997; 9: 148-154
        • Mingus ML
        • Monk TG
        • Gold MI
        • et al.
        Remifentanil versus propofol as adjuncts to regional anesthesia. Remifentanil 3010 Study Group.
        J Clin Anesth. 1998; 10: 46-53
        • Lauwers MH
        • Vanlersberghe C
        • Camu F.
        Comparison of remifentanil and propofol infusions for sedation during regional anesthesia.
        Reg Anesth Pain Med. 1998; 23: 64-70
        • Krenn H
        • Deusch E
        • Jellinek H
        • et al.
        Remifentanil or propofol for sedation during carotid endarterectomy under cervical plexus block.
        Br J Anaesth. 2002; 89: 637-640
        • Kheterpal S
        • Khodaparast O
        • Shanks A
        • et al.
        Chronic angiotensin-converting enzyme inhibitor or angiotensin receptor blocker therapy combined with diuretic therapy is associated with increased episodes of hypotension in noncardiac surgery.
        J Cardiothorac Vasc Anesth. 2008; 22: 180-186
        • Roshanov PS
        • Rochwerg B
        • Patel A
        • et al.
        Withholding versus continuing angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers before noncardiac surgery: An analysis of the vascular events in noncardiac surgery patients cohort evaluation prospective cohort.
        Anesthesiology. 2017; 126: 16-27
        • Setty S
        • Orza D
        • Belani KG.
        Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers before elective noncardiac surgery: An ongoing dilemma.
        Anesth Analg. 2018; 127: 598-600
        • Hollmann C
        • Fernandes NL
        • Biccard BM.
        A systematic review of outcomes associated with withholding or continuing angiotensin-converting enzyme inhibitors and angiotensin receptor blockers before noncardiac surgery.
        Anesth Analg. 2018; 127: 678-687
        • Mayr NP
        • Wiesner G
        • van der Starre P
        • et al.
        Dexmedetomidine versus propofol-opioid for sedation in transcatheter aortic valve implantation patients: A retrospective analysis of periprocedural gas exchange and hemodynamic support.
        Can J Anaesth. 2018; 65: 647-657
        • Chen EY
        • Sukumar N
        • Dai F
        • et al.
        A pilot analysis of the association between types of monitored anesthesia care drugs and outcomes in transfemoral aortic valve replacement performed without general anesthesia.
        J Cardiothorac Vasc Anesth. 2018; 32: 666-671
        • Kronfli AP
        • Lehman E
        • Yamane K
        • et al.
        Dexmedetomidine is an equal cost alternative to propofol in transcatheter aortic valve replacement, with equivalent in-hospital and 30-day outcomes.
        J Cardiothorac Vasc Anesth. 2021; 35: 439-445